CLEVELAND, March 14, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today the initiation of patient enrollment, and dosing of the first patient for a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem ®, Athersys' allogeneic cell therapy product for the treatment of ulcerative colitis (UC). This Phase II clinical trial is part of a strategic global collaboration between Athersys and Pfizer Inc. (NYSE:PFE) to investigate MultiStem for the treatment of inflammatory bowel disease (IBD).
The Phase II study is a randomized, double-blind, placebo-controlled, multi-center study designed to investigate the safety and efficacy of MultiStem in subjects with moderate to severe UC. The trial will be conducted at multiple clinical sites in North America and Europe, and is expected to include up to approximately 126 patients. Individuals participating in the study will receive multiple doses of either MultiStem or placebo, administered over a period of several weeks. Primary safety and efficacy endpoints will include endoscopic evaluation at baseline and at eight weeks, with a follow-up of all patients through twelve months.
"Despite treatment advances in recent years, Inflammatory Bowel Disease remains a debilitating condition for many individuals, and represents an area of substantial unmet medical need," said Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer of Athersys. "We're pleased with the continued progress of our partnership with Pfizer and excited about commencing the trial."Dr. Ruth McKernan, Head of Pfizer Regenerative Medicine, added: "Both teams have worked very well together, and we are pleased to be commencing this Phase II trial in this innovative area." About Inflammatory Bowel Disease According to Datamonitor, more than two million individuals in the United States, core European markets and Japan suffer from various forms of IBD, including Crohn's Disease and UC, which is the most commonly diagnosed form of IBD. UC is a chronic, relapsing inflammatory condition involving all or a portion of the colon. Patients with UC most commonly present with diarrhea, urgency, rectal bleeding, and abdominal pain. Patients may also experience fatigue, fevers, weight loss, and dehydration. The symptoms can be incapacitating.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV